Plasma levels of the MMP-9: TIMP-1 complex as prognostic biomarker in breast cancer: A retrospective study

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Thorsen, Stine B ^a   Christensen, Sarah L T ^a   Würtz, Sidse T ^a   Lundberg, Martin ^b   Nielsen, Birgitte S ^a   Vinther, Lena ^a   Knowles, Mick ^c   Gee, Nick ^c   Fredriksson, Simon ^b   Møller, Susanne ^d   Brünner, Nils ^a   Schrohl, Anne Sofie ^a   Stenvang, Jan ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b OLINK BIOSCIENCE   (Sweden)

^c Innova Biosciences   (United Kingdom)

^d Rigshospitalet   (Denmark)

Author keywords

Breast cancer; ELISA; Plasma MMP 9:TIMP 1 complex; Proximity ligation assay

Indexed keywords

AGED; BLOOD CHEMICAL ANALYSIS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIMIT OF DETECTION; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REFERENCE STANDARDS; RETROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 84890010393     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-598     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747. 10.1093/annonc/mdr304, 3144634, 21709140.
3. Moller S, Jensen MB, Ejlertsen B, Bjerre KD, Larsen M, Hansen HB, et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise. Acta Oncol 2008, 47:506-524. 10.1080/02841860802059259, 18465317.
4. Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997, 3:1623-1628.
5. Schrohl AS, Christensen IJ, Pedersen AN, Jensen V, Mouridsen H, Murphy G, et al. Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol Cell Proteomics 2003, 2:164-172. 10.1074/mcp.M300019-MCP200, 12672830.
6. Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004, 10:2289-2298. 10.1158/1078-0432.CCR-03-0360, 15073104.
7. Wu ZS, Wu Q, Yang JH, Wang HQ, Ding XD, Yang F, et al. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer 2008, 122:2050-2056. 10.1002/ijc.23337, 18172859.
8. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005, 11:5390-5395. 10.1158/1078-0432.CCR-04-2391, 16061852.
9. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174. 10.1038/nrc745, 11990853.
10. Roderfeld M, Graf J, Giese B, Salguero-Palacios R, Tschuschner A, Muller-Newen G, et al. Latent MMP-9 is bound to TIMP-1 before secretion. Biol Chem 2007, 388:1227-1234.
11. Patel S, Sumitra G, Koner BC, Saxena A. Role of serum matrix metalloproteinase-2 and -9 to predict breast cancer progression. Clin Biochem 2011, 44:869-872. 10.1016/j.clinbiochem.2011.04.019, 21565179.
12. Somiari SB, Somiari RI, Heckman CM, Olsen CH, Jordan RM, Russell SJ, et al. Circulating MMP2 and MMP9 in breast cancer - potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer 2006, 119:1403-1411. 10.1002/ijc.21989, 16615109.
13. Ranuncolo SM, Armanasco E, Cresta C, Bal De Kier JE, Puricelli L. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 2003, 106:745-751. 10.1002/ijc.11288, 12866035.
14. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004, 10:7621-7628. 10.1158/1078-0432.CCR-04-1061, 15569994.
15. Wurtz SO, Moller S, Mouridsen H, Hertel PB, Friis E, Brunner N. Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study. Mol Cell Proteomics 2008, 7:424-430.
16. Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002, 197:307-313. 10.1002/path.1129, 12115876.
17. McCarthy K, Maguire T, McGreal G, McDermott E, O'Higgins N, Duffy MJ. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer 1999, 84:44-48. 10.1002/(SICI)1097-0215(19990219)84:1<44::AID-IJC9>3.0.CO;2-P, 9988231.
18. Lambert E, Boudot C, Kadri Z, Soula-Rothhut M, Sowa ML, Mayeux P, et al. Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J 2003, 372:767-774. 10.1042/BJ20030187, 1223442, 12639219.
19. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998, 102:2002-2010. 10.1172/JCI2881, 509153, 9835626.
20. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002, 277:11069-11076. 10.1074/jbc.M111490200, 11796725.
21. Liu XW, Bernardo MM, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 2003, 278:40364-40372. 10.1074/jbc.M302999200, 12904305.
22. Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, et al. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005, 65:898-906.
23. Lee SJ, Yoo HJ, Bae YS, Kim HJ, Lee ST. TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src. Biochem Biophys Res Commun 2003, 312:1196-1201. 10.1016/j.bbrc.2003.11.050, 14652000.
24. Davidsen ML, Wurtz SO, Romer MU, Sorensen NM, Johansen SK, Christensen IJ, et al. TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Br J Cancer 2006, 95:1114-1120. 10.1038/sj.bjc.6603378, 2360707, 17047657.
25. Holten-Andersen MN, Murphy G, Nielsen HJ, Pedersen AN, Christensen IJ, Hoyer-Hansen G, et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999, 80:495-503. 10.1038/sj.bjc.6690384, 2362309, 10408859.
26. Jung KK, Liu XW, Chirco R, Fridman R, Kim HR. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006, 25:3934-3942. 10.1038/sj.emboj.7601281, 1560352, 16917503.
27. Jung YS, Liu XW, Chirco R, Warner RB, Fridman R, Kim HR. TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain. PLoS One 2012, 7:e38773. 10.1371/journal.pone.0038773, 3372473, 22701711.
28. Wurtz SO, Christensen IJ, Schrohl AS, Mouridsen H, Lademann U, Jensen V, et al. Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients. Mol Cell Proteomics 2005, 4:483-491. 10.1074/mcp.M400209-MCP200, 15640527.
29. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med 2012, 9:e1001216. 10.1371/journal.pmed.1001216, 3362085, 22675273.
30. Lundberg M, Thorsen SB, Assarsson E, Villablanca A, Tran B, Gee N, et al. Multiplexed homogeneous proximity ligation assays for high-throughput protein biomarker research in serological material. Mol Cell Proteomics 2011, 10:M110.
31. Thaysen-Andersen M, Thogersen IB, Nielsen HJ, Lademann U, Brunner N, Enghild JJ, et al. Rapid and individual-specific glycoprofiling of the low abundance N-glycosylated protein tissue inhibitor of metalloproteinases-1. Mol Cell Proteomics 2007, 6:638-647. 10.1074/mcp.M600407-MCP200, 17205978.
32. Roeb E, Behrmann I, Grotzinger J, Breuer B, Matern S. An MMP-9 mutant without gelatinolytic activity as a novel TIMP-1-antagonist. FASEB J 2000, 14:1671-1673.
33. Kuvaja P, Wurtz SO, Talvensaari-Mattila A, Brunner N, Paakko P, Turpeenniemi-Hujanen T. High serum TIMP-1 correlates with poor prognosis in breast carcinoma - a validation study. Cancer Biomark 2007, 3:293-300.
34. Schrohl AS, Mueller V, Christensen IJ, Pantel K, Thomssen C, Bruenner N. A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer. Tumour Biol 2008, 29:181-187. 10.1159/000146863, 18645261.
35. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-839. 10.1161/01.RES.0000070112.80711.3D, 12730128.
36. Vempati P, Karagiannis ED, Popel AS. A biochemical model of matrix metalloproteinase 9 activation and inhibition. J Biol Chem 2007, 282:37585-37596. 10.1074/jbc.M611500200, 17848556.